(Q62025762)

English

Comparison of The Effects of Thiazolidinediones(TZD), Sodium- Glucose Cotransporter 2 Inhibitors(SGLT2i) Alone and TZD / SGLT2i Combination Therapy on Non-alcoholic Fatty Liver Disease in Type 2 Diabetic Patients With Fatty Liver

clinical trial

In more languages

edit

Statements

instance of

clinical trial

0 references

title

Comparison of The Effects of Thiazolidinediones(TZD), Sodium- Glucose Cotransporter 2 Inhibitors(SGLT2i) Alone and TZD / SGLT2i Combination Therapy on Non-alcoholic Fatty Liver Disease in Type 2 Diabetic Patients With Fatty Liver (English)

0 references

medical condition

metabolic dysfunction–associated steatotic liver disease

0 references

sponsor

Yonsei University

0 references

start time

March 2019

0 references

end time

September 2020

0 references

number of participants

60

0 references

research intervention

pioglitazone

0 references

empagliflozin

0 references

2,4-thiazolidinedione

0 references

clinical trial phase

phase IV clinical trial

0 references

research subject recruitment status

not yet recruiting

0 references

minimum age

19 year

0 references

maximum age

75 year

0 references

study type

interventional study

0 references

Identifiers

ClinicalTrials.gov ID

NCT03646292

0 references

(Q62025762)

Comparison of The Effects of Thiazolidinediones(TZD), Sodium- Glucose Cotransporter 2 Inhibitors(SGLT2i) Alone and TZD / SGLT2i Combination Therapy on Non-alcoholic Fatty Liver Disease in Type 2 Diabetic Patients With Fatty Liver

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)